Clinical Trial Details
| Trial ID: | L6354 |
| Source ID: | NCT00239187 |
| Associated Drug: | E1 And G1 |
| Title: | A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes |
| Interventions: | DRUG: E1 and G1 |
| Outcome Measures: | Primary: To assess the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes | Secondary: To evaluate the pharmacokinetics (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes |
| Sponsor/Collaborators: | Sponsor: OPKO Health, Inc. |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 30 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT |
| Start Date: | 2005-09 |
| Completion Date: | 2007-01 |
| Results First Posted: | |
| Last Update Posted: | 2019-10-18 |
| Locations: | Profil Institute for Clinical Research Inc., Chula Vista, California, 91911, United States|Clinical Research of West Florida, Clearwater, Florida, 33765-2616, United States|Diabetes and Glandular Disease Research Associates, San Antonio, Texas, 78229-4801, United States |
| URL: | https://clinicaltrials.gov/show/NCT00239187 |
